Close
  Indian J Med Microbiol
 

Figure 2: Lappaconitine hydrochloride suppressed HepG2 cell viability and proliferation. (a) HUVEC, U251, HeLa, A549, and HepG2 cells were treated with lappaconitine hydrochloride for 48 h, and cell viability was determined by CCK-8. (b) Cell viability was determined by CCK-8 after incubation with lappaconitine for 24 h and 48 h. (c) Cell viability was determined by CCK-8 after incubation with lappaconitine hydrochloride for 24 h and 48 h. (d) 5-ethynyl-2′-deoxyuridine proliferation assay was used to test cell proliferation. (e) Graph illustrating the ratios of 5-ethynyl-2′-deoxyuridine-positive cells/total cells. Date are reported as mean ± standard deviation (n = 3). *P < 0.05, **P < 0.01 compared with the control. Scale bar = 20 μm

Figure 2: Lappaconitine hydrochloride suppressed HepG2 cell viability and proliferation. (a) HUVEC, U251, HeLa, A549, and HepG2 cells were treated with lappaconitine hydrochloride for 48 h, and cell viability was determined by CCK-8. (b) Cell viability was determined by CCK-8 after incubation with lappaconitine for 24 h and 48 h. (c) Cell viability was determined by CCK-8 after incubation with lappaconitine hydrochloride for 24 h and 48 h. (d) 5-ethynyl-2′-deoxyuridine proliferation assay was used to test cell proliferation. (e) Graph illustrating the ratios of 5-ethynyl-2′-deoxyuridine-positive cells/total cells. Date are reported as mean ± standard deviation (<i>n</i> = 3). *<i>P</i> < 0.05, **<i>P</i> < 0.01 compared with the control. Scale bar = 20 μm